07:25 AM EDT, 09/25/2024 (MT Newswires) -- Merck ( MRK ) said Wednesday that Japan's Ministry of Health, Labor and Welfare has approved new indications for Keytruda (pembrolizumab) in certain lung and urothelial cancers.

Keytruda in combination with Padcev was approved as a first-line treatment of patients with radically inoperable urothelial carcinoma, Merck ( MRK ) said.

The cancer drug was also approved for patients with inoperable urothelial carcinoma who are ineligible for any platinum-containing chemotherapy, the company said.

Japanese regulators also approved Keytruda in combination with chemotherapy as a neoadjuvant treatment, then continued as monotherapy as an adjuvant treatment, for patients with non-small cell lung carcinoma, Merck ( MRK ) said.

Price: 115.19, Change: +0.23, Percent Change: +0.20